Supplementary Materials

Supplementary Material for:

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

David L. Porter,* Wei-Ting Hwang, Noelle V. Frey, Simon F. Lacey, Pamela A. Shaw, Alison W. Loren, Adam Bagg, Katherine T. Marcucci, Angela Shen, Vanessa Gonzalez, David Ambrose, Stephan A. Grupp, Anne Chew, Zhaohui Zheng, Michael C. Milone, Bruce L. Levine, Jan J. Melenhorst, Carl H. June*

*Corresponding author. E-mail: david.porter{at}uphs.upenn.edu (D.L.P.); cjune{at}exchange.upenn.edu (C.H.J.)

Published 2 September 2015, Sci. Transl. Med. 7, 303ra139 (2015)
DOI: 10.1126/scitranslmed.aac5415

This PDF file includes:

  • Fig. S1. Consort diagram.
  • Fig. S2. CTL019 cells are polyfunctional.
  • Fig. S3. Example of serum ferritin response to tocilizumab in a patient with CRS.
  • Fig. S4. Association of peak CTL019 expansion with CRS and the response observed within the first 3 months after infusion.
  • Table S1. Cell dose and product characteristics (N = 14).
  • Table S2. Tumor burden assessed by IgH deep sequencing analysis of blood and bone marrow of all study subjects.
  • Table S3. Association of pretreatment characteristics with response.
  • Table S4A. Penn Grading System for CTL019-associated CRS.
  • Table S4B. Definition of high-dose vasopressors.
  • Table S5. Association of pretreatment characteristics with CRS (N = 14).

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S6. Source data for Fig. 1 (Excel).
  • Table S7. Source data for Fig. 2 (Excel).
  • Table S8. Source data for Fig. 3 (Excel).
  • Table S9. Source data for Fig. 4A (Excel).
  • Table S10. Source data for Fig. 4C (Excel).
  • Table S11. Source data for Fig. 5 (Excel).

[Download Tables S6 to S11]